The BTG3 Knockout HeLa Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal cell population in which the BTG3 tumor suppressor gene has been disrupted via CRISPR/Cas9-mediated gene targeting. This loss-of-function model is generated in the HeLa host cell line and provides a versatile tool for investigating the biological roles of BTG3 in cell cycle regulation, apoptosis, and DNA damage response. As a polyclonal knockout population, it retains heterogeneous editing events across the cell pool, enabling robust functional assays without clonal selection artifacts.
Host HeLa cells are an immortalized epithelial cell line originally derived from a cervical adenocarcinoma of Henrietta Lacks in 1951. These cells are widely employed in cancer research and cell biology due to their robust growth, ease of manipulation, and relevance to human papillomavirus-related carcinogenesis. HeLa cells exhibit characteristic features of cervical cancer, including altered p53 and Rb pathways, making them a suitable context for examining the interplay between viral oncoproteins and cellular tumor suppressors such as BTG3.
BTG3 (B-cell translocation gene 3) functions as a p53-inducible tumor suppressor that mediates cell cycle arrest at the G1/S transition and promotes apoptosis. Mechanistically, BTG3 directly binds to the transcription factor E2F1 and represses its transcriptional activity, leading to decreased expression of E2F1 target genes such as Cyclin D1 and CDK4, and consequent inhibition of Rb phosphorylation. BTG3 also interacts with the CCR4-NOT deadenylase complex, including CAF1, to regulate mRNA stability. This integration into the p53 signaling network positions BTG3 as a key downstream effector: DNA damage and chemotherapeutic agents activate p53, which transcriptionally upregulates BTG3, in turn modulating downstream targets like p21, Bax, and PUMA, and ultimately driving caspase-3-mediated apoptosis. Additional interacting partners, including HDAC1, Sin3A, and PCAF, further fine-tune its transcriptional regulatory functions.
Disruption of BTG3 in the HeLa cervical adenocarcinoma background offers a physiologically relevant platform to dissect tumor suppressor mechanisms in a cancer type where BTG3 expression is frequently attenuated. The HeLa line??s HPV-18-positive status and associated p53 degradation by E6 provide a unique context to study p53-independent roles of BTG3 or residual p53-dependent functions under stress. This knockout model allows researchers to assess how loss of BTG3 impacts proliferation, survival, and drug sensitivity in an oncogenic environment, thereby shedding light on its potential as a therapeutic target or biomarker in HPV-associated malignancies.
Researchers can utilize these BTG3 knockout HeLa cells in a wide array of functional studies, including cell viability assays (MTT), cell cycle analysis by propidium iodide flow cytometry, apoptosis detection with Annexin V/PI staining, and Western blot analysis for key effectors like BTG3, p21, and Bax. The model is also suited for RT-qPCR expression profiling, colony formation assays, migration and invasion studies, and drug sensitivity screens to evaluate chemotherapeutic responses. By providing a consistent and reproducible loss-of-function system, this product accelerates cancer drug screening and mechanistic investigations into tumor suppression. For additional details, please contact Ascent Research.
